Compare · IRD vs LLY
IRD vs LLY
Side-by-side comparison of Opus Genetics Inc. (IRD) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRD and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.35T, about 3828.8x IRD ($351.9M).
- LLY has been more active in the news (34 items in the past 4 weeks vs 14 for IRD).
- LLY has more recent analyst coverage (25 ratings vs 14 for IRD).
- Company
- Opus Genetics Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- $351.9M
- $1.35T
- 1M return
- -
- +21.13%
- 1Y return
- -
- +44.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 14
- 34
- Recent ratings
- 14
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest IRD
- SEC Form 10-Q filed by Opus Genetics Inc.
- Opus Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update
- Chief Executive Officer Magrath George sold $110,184 worth of shares (28,258 units at $3.90), decreasing direct ownership by 1% to 2,010,636 units (SEC Form 4) to satisfy withholding tax
- Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
- Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
- Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
- Chief Operating Officer Schachle Joseph K sold $16,994 worth of shares (4,767 units at $3.57) (SEC Form 4)
- President Yerxa Benjamin R sold $117,365 worth of shares (33,189 units at $3.54) (SEC Form 4)
Latest LLY
- EVP & President, LLY Int'l Jonsson Patrik gifted 704 shares, decreasing direct ownership by 1% to 53,443 units (SEC Form 4)
- Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
- Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
- Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
- President, Chair, and CEO Ricks David A gifted 23,538 shares (SEC Form 4)
- Treasury's Refunding Details Are Up Next as Five Large Companies Report Higher Revenue
- EVP, CS&PO & Pres. LRL Skovronsky Daniel gifted 119 shares, decreasing direct ownership by 0.07% to 159,953 units (SEC Form 4)